期刊文献+

检疫期管理不合格血浆分析

Analysis of rejected plasma of inventory hold
下载PDF
导出
摘要 目的分析原料血浆检疫期管理的有效性和不同类型检疫期不合格血浆的风险差异。方法 2011-2014年采用ELISA法合计检测3 257 272份原料血浆的HBs Ag、抗-HCV、抗-HIV,剔除检测不合格血浆及其献血浆者的检疫期不合格血浆,供血浆90 d后1年内无后续检测信息按无后续信息的检疫期不合格血浆处置,统计检疫期血浆的不合格率和HBs Ag、抗-HCV、抗-HIV检测阳性追踪的以及无后续检测信息的检疫期不合格血浆比例;对2013年检疫期不合格血浆做NAT检测,比较不同类型检疫期不合格血浆风险。结果本组2011-2014年检疫期不合格率0.025%(801/3 257 272),检测不合格率0.002%(76/3 257 272)(P<0.01);不同类型检疫期不合格血浆中HBs Ag和抗-HIV检测不合格追踪的检疫期不合格血浆分别占36.95%(296/801)、35.21%(282/801);2013年ELISA阴性的检疫期不合格血浆的NAT阳性率为18.62%(46/247),其中HBV、HCV、HIV分别占同类型检疫期不合格血浆的34.29%(36/105)、6.67%(2/30)、9.76%(8/82),无后续信息产生的检疫期不合格血浆的HBV/HCV/HIV NAT检测均为阴性。结论检疫期管理制度能剔除窗口期漏检血浆,进一步提高原料血浆的安全性;无后续信息的检疫期不合格血浆的风险远低于检测不合格追踪的检疫期不合格血浆,后者中又以HBV风险最大。 Objective To analyze the efficacy of quarantinemanagement of source plasma,as well as the risk of different types of rejected plasma in quarantine period. Methods A total of 3 257 272 donations,collected in 2011- 2014,were tested by ELISA kits for HBs Ag,HCV antibody,HIV antibody,respectively. Rejected donations that did not pass testing and the corresponding rejected donations in thequarantine period were eliminated. If there was no further testing information after90 days and within 1 year since the last donation,the donation was defined as rejected donation with no further information. The ratio of rejected donations and the ratio of different types of rejected donations were calculated. NAT testing was performed on rejected donations in quarantine period in 2013. The risks of different types of rejected donations were compared. Results A total of 801 rejected donations were eliminated in 2011- 2014,accounting for 0. 025% o( 801 /3 257 272) f the total plasma. The ratio of rejected donations ofquarantine period was much higher than that of retesting. Among the rejected plasma of different types in thequarantine period,the ratios of rejected plasma for HBs Ag and HIV antibody were relatively higher,accounting for 36. 95%( 296 / 801) and 35. 21%( 282 / 801),respectively. NAT testing was performed on 247 rejected donations duringquarantine periodin 2013 which were negative by ELISA. 18. 62%( 46 /247) donations were NAT positive,among them HBV,HCV,HIV NAT positive donations were 36,2,and 8 bags,accounting for 34. 29%( 36 /105),6. 67%( 2 /30),and 9. 76%( 8 /82),respectively. Rejected donations with no further information were all negative for HBV / HCV /HIV NAT. Conclusion Quarantinemanagement can eliminatewindow period plasma,and then canfurther enhance the safety of source plasma. According to the study,the risk of rejected donations with no further information is much lower than that of rejected donations that failed quarantine testing. The risk of HBV is the highest in rejected donat
出处 《中国输血杂志》 CAS 北大核心 2015年第12期1478-1481,共4页 Chinese Journal of Blood Transfusion
关键词 原料血浆 检疫期 酶联免疫试验 核酸检测 检测窗口期 source plasma inventory hold ELISA NAT window period
  • 相关文献

参考文献17

  • 1王迅.核酸检测技术(NAT)及其在血液筛检中的应用[J].中国输血杂志,2004,17(6):465-468. 被引量:30
  • 2PPTA . QSEAL inventory hold standard. Version 1.0. Implemen- ted 2000. 2013 by PPTA [2015-06-01 ] http://www, pptaglobal. org/en/qualitysafety_qseal, cfm. 被引量:1
  • 3国家食品药品监督管理局.关于实施血液制品生产用原料血浆检疫期的通知.国食药监安[2007]447号. 被引量:1
  • 4国家食品药品监督管理局.实施原料血浆检疫期管理技术指导原则.食药监办[2008]14.4号. 被引量:1
  • 5Waytes AT, Igel H , Zerlauth G, et al. A safer plasma supply from remunerated donors. San Fransisco:lntemational Symposium on Advances in Transfusion Safety, ETATS-UNIS ( 18/03/1999 ), 2000,102(251 p. ) (bibl: dissem. ) :37-51. 被引量:1
  • 6Storch H, Ponsel G, Igel H, et al. Plasma donor screening and product safety. Beitr Infusionsther Transfusionsmed, 1997,34( 1 ) : 31-36. 被引量:1
  • 7国家药典委员会.血液制品生产用人血浆.中华人民共和国药典(2010版三部):12-14.2010-07-01. 被引量:1
  • 8中华人民共和国卫生部.单采血浆站技术操作规程(2011版).2011-03-28. 被引量:1
  • 9European Pharmacopoeia Commission. Validation of nucleic acid amplification techniques(NAT) for the detection of hepatitis C vi- rus(HCV) RNA in plasma pools: guidelines. European Pharmaco- poeia 8.0:206-207. 2014-01-01. 被引量:1
  • 10FDA. Guidance for Industry: use of nucleic acid tests on pooled and individual samples fi'om donors of whole blood and blood Corn-ponents, including source plasma, to reduce the risk of transmis- sion of hepatitis B virus, 2012-10 [2013-09-10] http://www, fda. gov/regulatoryinformation/guidances/ucm327850, htm. http:// www. fda. gov/BiologicsBloodVaccines/GuidanceComplianceRegu- latorylnformation/Guidance~/Blood/ucm077067, htm. 被引量:1

二级参考文献69

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部